Profile
Russell Hawkinson worked as Vice President-Finance & Accounting at CTI BioPharma Corp.
from 2006 to 2007.
He then worked as Vice President-Finance at Corixa Corp.
from 1995 to 2005.
From 2007 to 2018, he served as Chief Financial Officer at Theraclone Sciences, Inc. He also worked as an Audit Senior Manager at Ernst & Young LLP (Missouri).
In addition, he worked as Chief Financial Officer at OncoResponse, Inc. from 2015 to 2018.
Most recently, he served as Senior Vice President-Finance at Silverback Therapeutics, Inc. from 2020 to 2022.
Mr. Hawkinson received his undergraduate degree from the University of Washington.
Former positions of Russell Hawkinson
| Companies | Position | End |
|---|---|---|
Theraclone Sciences, Inc.
 Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Director of Finance/CFO | 2018-05-31 |
OncoResponse, Inc.
 OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Director of Finance/CFO | 2018-05-31 |
| CTI BIOPHARMA CORP. | Director of Finance/CFO | 2006-12-31 |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Director of Finance/CFO | 2004-12-31 |
| ARS PHARMACEUTICALS, INC. | Director of Finance/CFO | - |
Training of Russell Hawkinson
| University of Washington | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Commercial Services |
Ernst & Young LLP (Missouri)
 Ernst & Young LLP (Missouri) Miscellaneous Commercial ServicesCommercial Services Ernst & Young provides accounting services. Its services include auditing, accounting, tax and transaction services, assurance and advisory business, online transaction advisory and a wide range of financial services. The company was founded by Arthur Young and Alwin C. Ernst in 1881 and is headquartered in Kansas City, MO. | Commercial Services |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson January 4, 2016 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Russell Hawkinson